AnaptysBio Posts Topline Data From ANB032 Study In Healthy Volunteers

Loading...
Loading...
  • AnaptysBio Inc ANAB announced topline data from a Phase 1 trial of ANB032, an anti-BTLA agonist antibody. 
  • Topline data demonstrated favorable safety, tolerability, and rapid and sustained pharmacokinetics and pharmacodynamic profile, supporting the advancement of ANB032 into subsequent patient trials.
  • ANB032 was generally well-tolerated, and no dose-limiting toxicities were observed.
  • The Company said that ANB032 demonstrated rapid and sustained target engagement on T cells and B cells. Reduction of cell surface BTLA expression and the shedding of a portion of the cell surface BTLA as soluble BTLA was observed.
  • AnaptysBio has a strategic portfolio review ongoing while continuing to execute on the development of its three antibody programs:
  • Imsidolimab topline data from the GEMINI-1 Phase 3 trial in generalized pustular psoriasis and HARP Phase 2 trial in hidradenitis suppurativa is anticipated in Q4 of 2023 and Q3 of 2022, respectively.
  • Related: AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne.
  • Rosnilimab topline data from the AZURE Phase 2 trial in moderate-to-severe alopecia areata is anticipated in 1H of 2023
  • ANB032 IND filing of Phase 2 trial is anticipated in 2H of 2022.
  • Price Action: ANAB shares closed at $22.50 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...